The agenda for the 18 February 2015 meeting of the Transparency Commission is now available. The Commission will consider the following medicines:

• Ezetimibe with atorvastatin calcium (Liptuzet) - new combination product
• Ledipasvir with sofosbuvir (Harvoni) - new combination product
• Ombitasvir with paritaprevir and ritonavir and dasabuvir (Viekiera Pak) - new combination product
• Enzalutamide (Xtandi) - new indication
• Budesonide with eformoterol fumarate dihydrate (DuoResp Spiromax) - new combination product
• Ibrutinib (Imbrivica) - new medicine
• Idelalisib (Zydelig) - new medicines

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-02/odj_ct_18022015_internet.pdf [French]